Prelude Therapeutics, Inc. PRLD 深 沪
等待开盘 05-12 09:30:00 美东时间
4.80
-0.060
-1.23%
华盛通- 最 高5.315
- 今 开4.85
- 成交量 34.74万股
- 最 低 4.32
- 昨 收 4.86
- 总市值 22.89万
- 52周最高 5.54
- 市盈率 静 --
- 换手率 728.28%
- 52周最低 0.75
- 委 比 62.34%
- 总股本 4.77万
- 历史最高 95.375
- 量 比 0.58
- 振 幅 20.47%
- 历史最低 0.6101
- 每 手 1
- 风险率 1.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Prelude Therapeutics Prices $90M Offering of 18M Shares At $4.44 Per Share
In lieu of Common Stock to investors who so chose, pre-funded warrants to purchase up to 2,252,252 shares of its Common Stock at a price of $4.4399 per pre-funded warrant, which represents the per share offering price
04-20 18:32
Dow Dips Over 400 Points; Pfizer Earnings Top Estimates
U.S. stocks traded lower this morning, with the Dow Jones index falling more th...
2025-11-04 22:53
Market-Moving News for November 4th
PRLD: 70% | Prelude Therapeutics Signs Agreement For Incyte To Acquire JAK2V617F JH2 Inhibitor Program In Development For Patients With Myeloproliferative Neoplasms NSP: -32% | Insperity shares are trading
2025-11-04 20:24
【开源零售|周视角】武商集团布局仓储会员店，探索本土化成长路径
（来源：泽鹏商业观察） 武商WS江豚会员店落地武汉，发力差异化商品与服务 武商集团入局仓储制会员店，发力差异化商品与服务。武商集团旗下首家会员制商店W...
2025-08-10 20:36
宁德时代旗下的子公司完成首轮数十亿元融资 ｜投资速递
来源：IT桔子 2025 年 7 月 28 日 IT 桔子（itjuzi521） 收录 13 起投资/IPO排队事件 国内投资事件 1...
2025-07-29 12:05
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
Prelude Therapeutics announced it will participate in two upcoming healthcare conferences in June. Kris Vaddi, CEO, will attend Jefferies Global Healthcare Conference on June 5 and Goldman Sachs 46th Annual Global Healthcare Conference on June 11. Both sessions will be available via live webcast on the company's website, with recordings archived for 90 days.
2025-06-02 11:30
Prelude Therapeutics FY Sales $7.000M Beat $2.000M Estimate
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly sales of $7.000 million which beat the analyst consensus estimate of $2.000 million by 250.00 percent.
2025-03-10 19:46
Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Initial Clinical Activity And Safety Profile In Phase 1 Trial
- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose
2024-09-13 22:03
HC Wainwright & Co. Reiterates Neutral on Prelude Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Neutral and maintains $5 price target.
2024-08-15 18:36
